Form 4 for MNPR Monopar Therapeutics
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-31 · accession 0001437749-23-000169 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-03 | 2022-12-31 | MNPR | Cittadine Andrew | COO | M - OptEx | — | +4,062 | 28.3K | +17% | — |
| D | 2023-01-03 | 2022-12-31 | MNPR | Cittadine Andrew | COO | F - Tax | $2.37 | -1,406 | 26.9K | -5% | -$3,332 |
| D | 2023-01-03 | 2022-12-31 | MNPR | Cittadine Andrew | COO | M - OptEx | $0.00 | -4,062 | 48.8K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-31 | M | A | 4,062 | — | 28,300 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 2 | Common | Common Stock | 2022-12-31 | F | D | 1,406 | $2.37 | 26,894 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-12-31 | M | D | 4,062 | $0.00 | 48,750 | D | — · — to — | 4,062 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F2) On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |